InvestorsHub Logo
Followers 0
Posts 7
Boards Moderated 0
Alias Born 11/11/2014

Re: dyp post# 24119

Friday, 07/20/2018 4:41:21 PM

Friday, July 20, 2018 4:41:21 PM

Post# of 34575






Kite Pharma, Inc. (NASDAQ:KITE), a clinical-stage biopharmaceutical firm pursuing novel cancer immunotherapy products, plans to raise $78.0 million in its upcoming IPO.

The Santa Monica, California-based firm will offer 6.0 million shares at an expected price range of $12-$14 per share. If the IPO can find the midpoint of that range, at $13 per share, KITE will command a market value of $548 million.

Kite was a clinical stage biopharmaceutical without a product and ended up at $17 a share on the day of its IPO. And we know the rest of the story. We offer a far superior product. So why do you think our share price is so overvalued? Am I missing something here?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRKR News